https://www.selleckchem.com/products/Nolvadex.html
Licensed dose second-generation H1-antihistamines (sgAHs) are the first-line treatment in chronic spontaneous urticaria (CSU). However, the available evidence up to the present is insufficient to rank sgAHs in terms of their efficacy. To study the comparative efficacy and acceptability of all licensed dose sgAHs in CSU treatment. We searched PubMed, Scopus, the Cochrane Central Register of Controlled Trials, and Web of Science for randomized controlled trials (RCTs) that included licensed dose sgAHs in CSU treatment up until March 2020
Like
Comment
Share
